Monte Rosa Therapeutics Inc’s recently made public that its 10% Owner Versant Venture Capital VI, L. unloaded Company’s shares for reported $7.4 million on Sep 20 ’24. In the deal valued at $6.53 per share,1,132,566 shares were sold. As a result of this transaction, Versant Venture Capital VI, L. now holds 5,099,336 shares worth roughly $25.5 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Versant Venture Capital VI, L. sold 541,897 shares, generating $3,251,382 in total proceeds. Upon selling the shares at $6.00, the 10% Owner now owns 6,257,218 shares.
Before that, Versant Venture Capital VI, L. sold 16,047 shares. Monte Rosa Therapeutics Inc shares valued at $96,309 were divested by the 10% Owner at a price of $6.00 per share. As a result of the transaction, Versant Venture Capital VI, L. now holds 6,241,171 shares, worth roughly $31.21 million.
Wedbush initiated its Monte Rosa Therapeutics Inc [GLUE] rating to an Outperform in a research note published on February 15, 2024; the price target was $11. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in early January from “an Equal weight” to “an Overweight”. UBS began covering GLUE with “Buy” recommendation on October 13, 2022. Jefferies started covering the stock on August 15, 2022. It rated GLUE as “a Buy”.
Price Performance Review of GLUE
On Tuesday, Monte Rosa Therapeutics Inc [NASDAQ:GLUE] saw its stock fall -1.38% to $5.00. Over the last five days, the stock has lost -5.66%. Monte Rosa Therapeutics Inc shares have fallen nearly -11.50% since the year began. Nevertheless, the stocks have fallen -1.38% over the past one year. While a 52-week high of $8.84 was reached on 03/26/24, a 52-week low of $2.44 was recorded on 06/28/24. SMA at 50 days reached $5.38, while 200 days put it at $5.35.
Levels Of Support And Resistance For GLUE Stock
The 24-hour chart illustrates a support level at 4.90, which if violated will result in even more drops to 4.81. On the upside, there is a resistance level at 5.14. A further resistance level may holdings at 5.29. The Relative Strength Index (RSI) on the 14-day chart is 40.87, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.42, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.84%. Stochastics %K at 6.93% indicates the stock is a buying.
How much short interest is there in Monte Rosa Therapeutics Inc?
A steep rise in short interest was recorded in Monte Rosa Therapeutics Inc stocks on 2024-09-13, growing by 0.48 million shares to a total of 3.27 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 2.79 million shares. There was a rise of 14.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 28, 2022 when Credit Suisse began covering the stock and recommended ‘”a Neutral”‘ rating along with a $19 price target.
